Cell Surface Lipoprotein Lipase Enzyme as A Prognostic Indicator in B-Cell Chronic Lymphocytic Leukemia

Author Info

Caleb J. Yelton Elaine Kuhn William B. Kinlaw Frederick Lansigan

Corresponding Author

Caleb J. Yelton
Dartmouth Medical Center, New Hampshire, United States

A B S T R A C T

Lipoprotein lipase (LPL) has emerged as a distinct prognostic marker for chronic lymphocytic leukemia (CLL), a heterogeneous disease with a similar heterogeneity in life expectancy. While many prior studies have focused on tumor expression of LPL mRNA, LPL surface protein expression has been less robustly studied as a prognostic marker. A novel antibody developed at Geisel School of Medicine at Dartmouth has been previously utilized in immunohistochemistry assays of breast and prostate cancer. With this study we aimed to use this antibody as a flow cytometry marker of surface LPL expression correlated with overall survival and time to first treatment. Of the 19 patients studied, our data show that LPL surface protein expression as measured by flow cytometry trended toward a protective effect on overall survival and overall better prognosis.

Article Info

Article Type

Research Article

Publication history

Received: Thu 23, Feb 2023
Accepted: Thu 11, May 2023
Published: Wed 14, Jun 2023

Copyright

© 2023 Caleb J. Yelton. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.ACO.2023.01.02